Valerio Therapeutics, Abivax Enter R&D Collaboration for Inflammatory Disease Therapies

MT Newswires Live07-16 18:08

Valerio Therapeutics said Thursday it has entered into a binding term sheet with Abivax (ABVX) for an exclusive worldwide research and development collaboration to develop next-generation therapies for immune-mediated inflammatory diseases.

Under the agreement, the company said it could receive up to 2.4 million euros ($2.8 million) upfront, along with potential development and commercial milestone payments and royalties, subject to the execution of a definitive co-ownership and license agreement.

The companies will collaborate on the discovery, manufacturing and preclinical evaluation of therapeutic candidates, with Abivax retaining the option to advance selected programs into further development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2651644362?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 18:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651644362","market":"us","top_or_hot":-1,"title":"Valerio Therapeutics, Abivax Enter R&D Collaboration for Inflammatory Disease Therapies","media":"MT Newswires Live","content":"<html><body><p> Valerio <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said Thursday it has entered into a binding term sheet with Abivax (ABVX) for an exclusive worldwide research and development collaboration to develop next-generation therapies for immune-mediated inflammatory diseases.</p><p>Under the agreement, the company said it could receive up to 2.4 million euros ($2.8 million) upfront, along with potential development and commercial milestone payments and royalties, subject to the execution of a definitive co-ownership and license agreement.</p><p>The companies will collaborate on the discovery, manufacturing and preclinical evaluation of therapeutic candidates, with Abivax retaining the option to advance selected programs into further development.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Valerio Therapeutics, Abivax Enter R&D Collaboration for Inflammatory Disease Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nValerio Therapeutics, Abivax Enter R&D Collaboration for Inflammatory Disease Therapies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-16 18:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Valerio <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said Thursday it has entered into a binding term sheet with Abivax (ABVX) for an exclusive worldwide research and development collaboration to develop next-generation therapies for immune-mediated inflammatory diseases.</p><p>Under the agreement, the company said it could receive up to 2.4 million euros ($2.8 million) upfront, along with potential development and commercial milestone payments and royalties, subject to the execution of a definitive co-ownership and license agreement.</p><p>The companies will collaborate on the discovery, manufacturing and preclinical evaluation of therapeutic candidates, with Abivax retaining the option to advance selected programs into further development.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2651644362","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651644362","pubTimestamp":1784196523,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Valerio Therapeutics said Thursday it has entered into a binding term sheet with Abivax  for an exclusive worldwide research and development collaboration to develop next-generation therapies for immune-mediated inflammatory diseases.Under the agreement, the company said it could receive up to 2.4 million euros  upfront, along with potential development and commercial milestone payments and royalties, subject to the execution of a definitive co-ownership and license agreement.The companies will collaborate on the discovery, manufacturing and preclinical evaluation of therapeutic candidates, with Abivax retaining the option to advance selected programs into further development.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4139":"生物科技","ABVX":"Abivax S.A.","BK4539":"次新股","BK4007":"制药"},"translate_title":"Valerio Therapeutics 与 Abivax 达成炎症性疾病疗法研发合作","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"ABVX":1},"content_text":"Valerio Therapeutics said Thursday it has entered into a binding term sheet with Abivax (ABVX) for an exclusive worldwide research and development collaboration to develop next-generation therapies for immune-mediated inflammatory diseases.Under the agreement, the company said it could receive up to 2.4 million euros ($2.8 million) upfront, along with potential development and commercial milestone payments and royalties, subject to the execution of a definitive co-ownership and license agreement.The companies will collaborate on the discovery, manufacturing and preclinical evaluation of therapeutic candidates, with Abivax retaining the option to advance selected programs into further development.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651644362","isCrawlerRequest":true}